On Sept. 8, 2022, the Food and Drug Administration (FDA) released a new safety communication about squamous cell carcinoma (SCC) and various lymphomas in the capsule around breast implants. This document is now available to healthcare providers, patients and caregivers on the FDA's Medical Device Safety webpage.

The American Society of Plastic Surgeons (ASPS)/The Plastic Surgery Foundation (PSF) has been in communication with the Food and Drug Administration (FDA) regarding this emerging issue. Data on this topic are limited and evolving; however, the Society would like to provide ASPS members with additional information specifically about Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC) to support increased clinical awareness and enhanced clinical decision-making as more evidence becomes available.

Read more at https://www.plasticsurgery.org/for-medical-professionals/publications/psn-extra/news/asps-statement-on-breast-implant-associated-squamous-cell-carcinoma